ライフサイエンスコーパス: LD50

1 LD50 studies indicated a small increase in retinol toxic

2 LD50 test results showed that mice could well sustain th

3 d subsequent lethal i.p. challenge of 10,000 LD50s, even in the absence of specific IgG Abs, as did m

4 vived a very strong i.p. challenge of 10,000 LD50s.

5 mice, and i.p. infection at a dose of 1,000x LD50 resulted in death between 6 and 8 days postinfectio

6 and C57BL/6 mice challenged i.p. with 2,000x LD50 of MARV/Ang-MA.

7 BoNT/A (1 LD50/ml) in 5 min and 0.4 fM (0.01 LD50/ml) in 5h.

8 , yielding a limit of quantification of 0.03 LD50/ml.

9 A sensitivity of 0.5 fM in 10% serum (0.1 LD50/ml serum) was attained when SNAP-25 was coupled dir

10 rotype-specific and detected 55 fM BoNT/A (1 LD50/ml) in 5 min and 0.4 fM (0.01 LD50/ml) in 5h.

11 taneously with 60 50% lethal doses (LD50) (1 LD50 = 1.9 CFU) of a virulent Y. pestis strain, CO92.

12 allenged with a potential working dose of 10 LD50 of MERS-CoV were subsequently evaluated.

13 ion and pathology in mice challenged with 10 LD50 of virus and utilized the model for preclinical eva

14 he challenged animals surviving a dose of 10 LD50s.

15 otected them against a ricin challenge of 10 LD50s.

16 all were fully immune to challenge with 100 LD50 of MERS-CoV.

17 protected rabbits against challenge with 100 LD50s of B. anthracis Ames spores, and 100% of the rabbi

18 s, 9 were also attenuated (40 to 100%) at 12 LD50 in a pneumonic plague mouse model.

19 ound to exhibit some attenuation at 11 or 12 LD50 in a mouse model of pneumonic plague.

20 protected upon subsequent challenge with 12 LD50 of WT CO92, suggesting that this mutant or others c

21 completely protected from challenge with 200 LD50 aerosolized anthrax spores.

22 gimens showed 78 to 93% survival after a 20x LD50 challenge with H10407, compared to 100% mortality i

23 the bioluminescent WT CO92 strain (20 to 28 LD50s), 40 to 70% of the mice survived, with efficient c

24 entration in the serum of mice exposed to 2x LD50 dose of TETS and to monitor kinetics of TETS cleara

25 ere protected from a lethal challenge with 3 LD50 of vaccinia virus strain WR (5/10 versus 0/10; P <

26 BoNT vaccine were challenged with 4 x 10(3) LD50 of BoNT type A (BoNT/A) via the i.p. route, complet

27 r survival rates at an infectious dose of 40 LD50.

28 with a more aggressive challenge dose of 41 LD50s.

29 ction seen in the mice challenged with 10(5) LD50 of MERS-CoV, we were able to recover infectious vir

30 alpp DeltamsbB DeltarbsA triple mutant at 50 LD50 were 90% protected upon subsequent challenge with 1

31 mice in a pneumonic plague model at 20 to 50 LD50.

32 d mouse model of infection [lethal dose 50% (LD50) = 101] than are E. coli strains that produce any o

33 model to calculate the lethal dose for 50% (LD50) of cells.

34 cisella tularensis strain LVS survived 10(6) LD50s of lethal challenge given only 3 days later.

35 macaques were exposed to approximately 1,600 LD50 of spores by aerosol.

36 n, 20/118 mutants exhibited attenuation at 8 LD50 when tested in a mouse model of bubonic plague, wit

37 a 50% lethal dose (LD50) equivalent to 6,800 LD50s of WT CO92.

38 r soman (100 microg/kg SC; equivalent to 0.9 LD50) or saline and observed for convulsive activity.

39 graded doses of Escherichia coli O111:B4, an LD50 was achieved at a dose of approximately 10(6) cfu.

40 A in mice for toxicity studies determined an LD50 of >2000 mg/kg body weight (bw) and 225 mg/kg bw, r

41 For the in vivo experiments, an LD50 dose (500 microg) of Escherichia coli LPS was injec

42 its parental ybt-, yfe+ strain, which had an LD50 of < 12.

43 ulmonary arterial catheters and underwent an LD50 cotton smoke inhalation injury via a tracheostomy u

44 Mice were challenged with an LD50 dose of intraperitoneal E. coli lipopolysaccharide

45 re yielded a synergistic interaction with an LD50 of 327 ng at 43 degrees C for 30 minutes.

46 found to have low toxicity in mice, with an LD50 of 590 +/- 66 mg/kg intraperitoneally, and rapid pl

47 displayed heterogeneous sensitivity, with an LD50 ranging from 4 muM to more than 200 muM.

48 ew days after median lethal dose (LD)100 and LD50 infection, while overall mortality did not differ f

49 -type = 13.12 Gy versus p50-/- = 7.75 Gy and LD50/Day 30: wild-type = 9.31 Gy versus p50-/- = 7.81 Gy

50 hen assayed for survival in host tissues and LD50 analysis.

51 xposed to 3-aminopropanal undergo apoptosis (LD50 = 160 microM), whereas neurons are killed by necrot

52 quired to replace the mouse lethality assay (LD50) in current use.

53 human sepsis, the implanted, infected clot (LD50 = 5-7 x 10(8) colony forming units/mL, n = 6) eleva

54 iated with a zebrafish embryo concentration, LD50, of 0.079 microg/g of embryo.

55 The 50% lethal dose (LD50) and mean time to death (MTD) of the mutants did no

56 al, with an intraperitoneal 50% lethal dose (LD50) approaching a single bacterium.

57 ng unable to kill mice at a 50% lethal dose (LD50) equivalent to 6,800 LD50s of WT CO92.

58 ur results suggest that the 50% lethal dose (LD50) falls within the range of 5 x 10(6) to 5 x 10(8) C

59 We estimated that the 50% lethal dose (LD50) for cervidized transgenic mice would be contained

60 SPBNgamma has a 50% lethal dose (LD50) more than 100-fold greater than SPBN(-).

61 t survived, compared to the 50% lethal dose (LD50) of 1.2 x 10(3) CFU for the wild-type strain.

62 tality, with an approximate 50% lethal dose (LD50) of 10(5) CFU, while an equivalent dose of CI 77 ex

63 We found that Stx2a had a 50% lethal dose (LD50) of 2.9 mug, but no morbidity occurred after oral i

64 al to these animals, with a 50% lethal dose (LD50) of 5.3 x 10(-2) 50% tissue culture infective doses

65 The 50% lethal dose (LD50) of alpha-factor for the calmodulin mutant is almos

66 resistance to 10,000 times the lethal dose (LD50) of BoNT/A, and transfusion of these red blood cell

67 i.p.) with 10,000 times the 50% lethal dose (LD50) of gp-adapted EBOV, and naive gps were then introd

68 Measuring the lethal dose (LD50) of HMCLs revealed that HMCLs displayed heterogeneo

69 Moreover, the 50% lethal dose (LD50) of L/ST-n38 was comparable to that of wild-type vi

70 primary leukemia samples with a lethal dose (LD50) of less than 10 microM in 16 of 27 (60%) samples.

71 eefold increase in the oral 50% lethal dose (LD50) of S. typhimurium for mice.

72 llenge dose three times the 50% lethal dose (LD50) of strain J45.

73 aimed at determining the median lethal dose (LD50) of the Bacillus anthracis Ames strain in guinea pi

74 lue gourami fish model: the 50% lethal dose (LD50) of the DeltaeseJ mutant is 2.34 times greater than

75 d doses up to 400 times the 50% lethal dose (LD50) of the parental virus.

76 50% infectious dose (ID50) and lethal dose (LD50) of virus were estimated to be <1 and 10 TCID50 of

77 utants was ascertained by a 50% lethal dose (LD50) study and by determining colonization ability with

78 jection route, LSU-E2 had a 50% lethal dose (LD50) that was greater than 5 logs10 higher than the LD5

79 The 50% lethal dose (LD50) values of these strains are increased 100- to 1,00

80 on alone demonstrated log10 50% lethal dose (LD50) values too great to be measured.

81 elate well with observed median lethal dose (LD50) values.

82 The median lethal dose (LD50) was determined to be 0.015 50% TCID50 (tissue cult

83 icity up to 500-fold of the 50% lethal dose (LD50) when it was injected systemically.

84 in small increases in mouse 50% lethal dose (LD50), deletions in both genes resulted in a 500-fold in

85 ged subcutaneously with 60 50% lethal doses (LD50) (1 LD50 = 1.9 CFU) of a virulent Y. pestis strain,

86 n.) challenge with ~240 median lethal doses (LD50) (2.4 x 10(4) CFU) of Y. pestis KIM6+(pCD1Ap) than

87 10(7) bacteria resulted in 50% lethal doses (LD50) in neonatal DBA/2 mice.

88 quently challenged with 10 50% lethal doses (LD50) of aerosolized highly virulent F. tularensis Schu

89 sal challenges with 1 or 5 50% lethal doses (LD50) of pathogenic vaccinia virus strain WR, demonstrat

90 BALB/c mice against 10,000 50% lethal doses (LD50) of S. Typhimurium or S. Enteritidis, respectively.

91 at a dose equivalent to 5 50% lethal doses (LD50) of wild-type (WT) CO92.

92 ses ranging from 50 to 500 50% lethal doses (LD50).

93 rA, ntrB, or ntrC had i.p. 50% lethal doses (LD50s) of <10 bacteria, similar to the wild-type strain.

94 mice, challenged with five 50% lethal doses (LD50s) of anthrax spores, were given a single 16.7-mg/kg

95 ithin 2 to 3 days with two 50% lethal doses (LD50s) of the WT bacterium.

96 al spore challenge with 24 50% lethal doses [LD50s] of B. anthracis Sterne and against rechallenge on

97 solized with 10(4) CFU (10 50% lethal doses [LD50s]).

98 an intravenous bolus injection of endotoxin (LD50 of E. coli lipopolysaccharide = 5.6 mg/kg, n = 7),

99 Using the estimated LD50 and ID50 data, we dissected the kinetics of viral t

100 ced hematopoietic syndrome (6.5 Gy exposure, LD50/30).

101 how genotoxicity in vitro and displayed high LD50 values in mice, making this prodrug 1r/drug 2r coup

102 ermal (i.d.) LVS infection has a much higher LD50, about 10(6) bacteria in BALB/cByJ mice, and surviv

103 ent of Temprid showed a significantly higher LD50 in selected strains, but susceptibility to the neon

104 -R-MDR49B isoform had a significantly higher LD50 value as compared to the 91-C-MDR49B isoform at the

105 3 were more active than isomers 2, with IC50/LD50 ranging from 25/233 nM (3i) to 1.3 (3a)/10.7 (3b) m

106 eveloped in the surviving mice from the ID50/LD50 determinations, and all were fully immune to challe

107 tion (an approximately 0.9 log difference in LD50).

108 fection as evidenced by a 5-fold increase in LD50 and increases in either percent survival or time to

109 a challenge dose with a fourfold increase in LD50 to 1,350 mg/kg.

110 oth genes resulted in a 500-fold increase in LD50.

111 mammalian cells, have dramatically increased LD50s in newborn mice, and induce high levels of protect

112 The inhaled LD50 of aerosolized Ames strain spores in guinea pigs wa

113 Intramuscular LD50 values for Cyto-012 and wt BoNT/A respectively, wer

114 The safety margin (intramuscular LD50/ED50 ratio) for Cyto-012 was found to be improved 2

115 ly avirulent in mice infected intravenously (LD50 > 1.7 x 107 cfu) compared with its parental ybt-, y

116 At six times the J45 LD50, J45-100 caused mild to moderate lung lesions but n

117 an NQO1-dependent manner by beta-lapachone (LD50, approximately 4 microM) with a minimum 2-h exposur

118 strain exhibited lower lethal dose 0 (LD0), LD50, and LD100, and dissemination in mice, with reduced

119 "corrected" Tyr6398/Leu94 virus had a log10 LD50 identical to wild-type MHV-A59.

120 Hemolysin production caused a 35-fold lower LD50 and a much shorter survival, similar to previous re

121 all of the B-CLL samples tested with a mean LD50 value (the concentration of drug required to kill 5

122 s neurons are killed by necrotic mechanisms (LD50 = 90 microM).

123 GSH synthetase correlated with PRIMA-1(Met) LD50 values, and we showed that a GSH decrease mediated

124 ation-induced lethality than wild-type mice (LD50/Day 7: wild-type = 13.12 Gy versus p50-/- = 7.75 Gy

125 13a was well tolerated in rodents (in mice, LD50 = 2326 mg/kg or higher), providing a relatively hig

126 LD50 (1 mouse LD50/ml) for BoNT B, 0.1 mouse LD50 (0.2 mouse LD50/ml) for BoNT E, and 0.5 mouse LD50

127 h), so that toxin levels lower than 1 mouse LD50 or 55 attomoles per milliliter (55 amol/mL) could b

128 A limit of detection of 0.1 mouse LD50/ml was achieved using the novel peptide substrate i

129 LD50/ml) for BoNT A, 0.5 mouse LD50 (1 mouse LD50/ml) for BoNT B, 0.1 mouse LD50 (0.2 mouse LD50/ml)

130 /ml) for BoNT E, and 0.5 mouse LD50 (1 mouse LD50/ml) for BoNT F.

131 in 500mul of spiked human serum are 10 mouse LD50 (20 mouse LD50/ml) for BoNT A, 0.5 mouse LD50 (1 mo

132 50/ml) for BoNT B, 0.1 mouse LD50 (0.2 mouse LD50/ml) for BoNT E, and 0.5 mouse LD50 (1 mouse LD50/ml

133 iked human serum are 10 mouse LD50 (20 mouse LD50/ml) for BoNT A, 0.5 mouse LD50 (1 mouse LD50/ml) fo

134 D50 (20 mouse LD50/ml) for BoNT A, 0.5 mouse LD50 (1 mouse LD50/ml) for BoNT B, 0.1 mouse LD50 (0.2 m

135 0.2 mouse LD50/ml) for BoNT E, and 0.5 mouse LD50 (1 mouse LD50/ml) for BoNT F.

136 The mouse LD50 of BoNT/C1 ad is 5 mg/kg, with transient neurologic

137 l proteins at a dose equivalent to 30 murine LD50 of SEB.

138 as completely attenuated for neurovirulence (LD50 > 10(6) PFU) relative to wild-type virus (LD50 < 90

139 No toxicity was observed (LD50 > 50 muM) against a panel of four mammalian cells l

140 a moderate nontoxic dose (9 mg/kg or ~1/5 of LD50 in rats) can cause fatal hyperthermia under environ

141 efficacy of this nasal BoNT vaccine, an oral LD50 was determined.

142 adruple mutant) had a 26-fold increased oral LD50.

143 tion with Delta(barA), it increased the oral LD50 24-fold.

144 The oral LD50 for a yopJ mutant Yersinia pseudotuberculosis incre

145 iven an oral challenge of 5 microg (2 x oral LD50) of progenitor BoNT/A, all immunized mice survived

146 delta(glnA-ntrC) operon deletion had an i.p. LD50 of >10(5) bacteria, as did delta glnA ntrA and delt

147 sequently challenged with 100,000 mouse i.p. LD50 of BoNT/A.

148 mouse intraperitoneal 50% lethal doses (i.p. LD50) of BoNT/A.

149 The oral potency (LD50) of toxin A and toxin B against Southern corn rootw

150 includes the guinea pig and nonhuman primate LD50s, but the observation that L. monocytogenes-induced

151 ly Adh3 -/- mice had a significantly reduced LD50 value.

152 An increase in the relative LD50 was found for RJ16 (bmaI1) (>967 CFU), RJ17 (bmaI3)

153 rol-exposed NQO1+ A549 cells were resistant (LD50, >40 microM) to ROS formation and all cytotoxic eff

154 native-Dam-overproducing strain at the same LD50 did not result in any lethality and provided protec

155 strains that produce any other type of Stx (LD50 = 1010).

156 The LD50 and LD100 were 9 x 10(7) and 12 x 10(7), respective

157 The LD50 for carboplatin exposure at 37 degrees C occurred a

158 The LD50 for hyperthermia at 40 degrees C occurred at 90 min

159 The LD50 of mouse-adapted EBO-Z virus inoculated into the pe

160 The LD50 of mouse-adapted EBO-Z virus inoculated into the pe

161 The LD50 value of [213Bi]J591 was 220 nCi/ml at a specific a

162 The LD50 was not affected by rhIL-11 but was 10-fold lower i

163 s model by determining both the ID50 and the LD50 of MERS-CoV in order to establish both an infection

164 selected to investigate the response at the LD50 and LD100 of C3Hf/Kam mice.

165 At the LD50 hemorrhage, peak lactate concentration and base def

166 lmodulin mutant is almost fivefold below the LD50 for a wild-type strain.

167 CNB1, from a wild-type strain decreases the LD50 of alpha-factor but has no further effect on a cmd1

168 CMK2 genes, which encode CaMK, decreases the LD50 of pheromone compared with that for a wild-type str

169 Furthermore, the LD50 and colonization studies revealed that there is no

170 Furthermore, the LD50 of alpha-factor for a mutant in which the calcineur

171 netics, as well as a 70-fold increase in the LD50 compared with wild type.

172 ractory, resulting in a 43% reduction in the LD50 from 4 to 2.3 micromol/L doxorubicin (P < 0.05).

173 ad an approximately 100-fold increase in the LD50 from a subcutaneous route of infection.

174 either antibiotic resulted in a shift in the LD50 of approximately 500-fold, in contrast to D-galacto

175 d mice, in which a < 10-fold increase in the LD50 was observed with antibiotic therapy.

176 reduces TNFalpha induction and increases the LD50 of this pathogenic bacteria by 10,000-fold.

177 terile rat fecal extracts (SRFE) lowered the LD50 of OG1RF >10-fold.

178 crog) of SN7-dgRA corresponded to 14% of the LD50 dose.

179 plete remissions are observed at 2.5% of the LD50.

180 dose of betaAP 25-35 was chosen based on the LD50 (28.9 microM) obtained in our earlier work.

181 at was greater than 5 logs10 higher than the LD50 for wild-type E. ictaluri.

182 mice even at doses 100-fold higher than the LD50 of the parent strain.

183 inoculation of guinea pigs revealed that the LD50 for the pilD mutant is at least 100-fold greater th

184 ramide generation (46 nM) was similar to the LD50 for clonogenic cell death (40 nM).

185 th UL24-betagluc at a dose equivalent to the LD50 of parental virus (approximately 5 x 10(3) PFU) was

186 that resembles human tularemia, whereas the LD50 for an intradermal infection is >10(6) organisms.

187 In line with the LD50, we propose a new index of "lethal imposed stress":

188 The LD50s or MTDs were also unaffected relative to those of

189 toneal model of infection, we determined the LD50s for wild-type B. mallei and each QS mutant.

190 attenuation phenotypes, as revealed by their LD50 values: PR8, 32 plaque-forming units (PFU); HA(Min)

191 imals, the ratios of plaque-forming units to LD50 decreased by at least four orders of magnitude to l

192 alter the ratios of plaque-forming units to LD50 or affect the HSV-induced increase in ganglionic Ig

193 are enriched for ICs that have acutely toxic LD50 doses or reactive functional groups.

194 e concentrations (EC50s) and the toxicities (LD50s) of the flavonoids after 24 hours, by using the MT

195 apoptosis was seen after beta-lap treatment (LD50 = 2.5 microM).

196 fection model, an inv mutant has a wild-type LD50, even though the kinetics of infection is changed.

197 50 > 10(6) PFU) relative to wild-type virus (LD50 < 900 PFU), although the four single-base-pair subs

198 iment in rats after oral administration with LD50 exceeding 2000 mg/kg of body weight.

199 y induced by apogossypol than gossypol, with LD50 values of 3 to 5 microM and 7.5 to 10 microM, respe

200 that rBD1 was well tolerated in rodents with LD50 values of 40 mg/kg in mice and >25 mg/kg in rats.

201 cing influenza A virus (IAV) survived the WT LD50 virus dose.

202 onferred 100% survival in response to a 10 x LD50 ricin challenge, whereas a 2:1 heterodimer:toxin ra

203 survived challenge with a lethal dose (10 x LD50) of MHV strain JHM, whereas mice administered wild-